- AU$595.43m
- AU$1.88bn
- AU$1.75bn
- 58
- 98
- 69
- 86
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 58.61 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.75 | ||
| Price to Tang. Book | 16.63 | ||
| Price to Free Cashflow | 2.73 | ||
| Price to Sales | 0.5 | ||
| EV to EBITDA | 7.78 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.08% | ||
| Return on Equity | -4.44% | ||
| Operating Margin | 0.11% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1,557 | 1,900.7 | 2,288.9 | 1,706.9 | 1,746.2 | 1,487.06 | 1,415.03 | 2.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +69.91 | -25.76 | +336.73 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Healius Limited is a healthcare company. The Company’s specialized pathology businesses deliver healthcare services across Australia. It provides pathology services, including specialty pathology and clinical trials. It offers its medical laboratory and pathology services through a variety of specialty brands. It provides medical laboratory and pathology services across key diagnostic activities. These include anatomical pathology (histopathology and cytology), clinical pathology (biochemistry, hematology, immunology and microbiology), genomic diagnostics and veterinary pathology. Its brands include QML, Laverty, Dorevitch, Western Diagnostic Pathology, TML, Agilex Biolabs, and Abbott Pathology, among others. These brands operate in Queensland, New South Wales (including the Australian Capital Territory), Victoria, Western Australia and Northern Territory, Tasmania, and South Australia. It provides specialty diagnostic services to consumers and their referring practitioners.
Directors
- Robert Hubbard NEC
- Malcolm Parmenter CEO
- Maxine Jaquet CFO
- Ben Korst CEX
- Dean Lewsam CEX
- John McKechnie CEX
- Mark Neeham OTH
- Janet Payne OTH
- Peter Wilson OTH
- Alison Stephenson SEC
- Charles Tilley SEC
- Gordon Davis NID
- Sally Louise Evans NID
- Paul Jones NID
- Jenny Macdonald NID
- Kathryn McKenzie NID (60)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 17th, 1994
- Public Since
- July 3rd, 1998
- No. of Shareholders
- 13,637
- No. of Employees
- 10,500
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 726,134,000
- Address
- Level 22, SYDNEY, 2000
- Web
- https://www.healius.com.au/
- Phone
- +61 294329400
- Auditors
- Ernst & Young
Latest News for HLS
Upcoming Events for HLS
Full Year 2025 Healius Ltd Earnings Release
Healius Ltd Annual Shareholders Meeting
Similar to HLS
Apiam Animal Health
Australian Stock Exchange - SEATS
Artrya
Australian Stock Exchange - SEATS
Australian Clinical Labs
Australian Stock Exchange - SEATS
Cann
Australian Stock Exchange - SEATS
Careteq
Australian Stock Exchange - SEATS
FAQ
As of Today at 03:03 UTC, shares in Healius are trading at AU$1.07. This share price information is delayed by 15 minutes.
Shares in Healius last closed at AU$1.07 and the price had moved by +15.5% over the past 365 days. In terms of relative price strength the Healius share price has outperformed the ASX All Ordinaries Index by +10.18% over the past year.
The overall consensus recommendation for Healius is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreHealius does not currently pay a dividend.
Healius does not currently pay a dividend.
Healius does not currently pay a dividend.
To buy shares in Healius you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$1.07, shares in Healius had a market capitalisation of AU$773.33m.
Here are the trading details for Healius:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: HLS
Based on an overall assessment of its quality, value and momentum Healius is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Healius is AU$1.25. That is 17.28% above the last closing price of AU$1.07.
Analysts covering Healius currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Healius. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +9.3%.
As of the last closing price of AU$1.07, shares in Healius were trading -2.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Healius PE ratio based on its reported earnings over the past 12 months is 58.61. The shares last closed at AU$1.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Healius' management team is headed by:
- Robert Hubbard - NEC
- Malcolm Parmenter - CEO
- Maxine Jaquet - CFO
- Ben Korst - CEX
- Dean Lewsam - CEX
- John McKechnie - CEX
- Mark Neeham - OTH
- Janet Payne - OTH
- Peter Wilson - OTH
- Alison Stephenson - SEC
- Charles Tilley - SEC
- Gordon Davis - NID
- Sally Louise Evans - NID
- Paul Jones - NID
- Jenny Macdonald - NID
- Kathryn McKenzie - NID